Revvity, Inc. unveiled the VivoJect Image-Guided Injection System as part of its cancer research and discovery portfolio at the AACR Annual Meeting 2025 in Chicago, April 25-30.
Paired with the Vega automated preclinical ultrasound system, the VivoJect system allows for real-time imaging and precise, nimble operation for researchers at a higher throughput compared to traditional techniques. It streamlines in vivo imaging workflows for applications such as tumor model creation, targeted drug delivery, gene therapy, stem cell research, and cardiac studies.
Revvity also showcased a broad portfolio of solutions driving advancements in cancer research at its booth (#1200), including the PhenoVue DNA Damage Response Staining Kit, Harmony 5.3 and Phenologic.AI high-content image analysis software and over 120 cell line-derived oncology reference standards from its Mimix portfolio. BioLegend’s reagent innovations will also be on display, including the TotalSeq PhenoCyte, TotalSeq-A and -C Universal Cocktails, v2.0, LEGEND MAX High Sensitivity Mouse TNF-a and ELISA MAX Deluxe Set Human ICAM-1 kits.
All Revvity offerings mentioned herein are for research use only, and not for use in diagnostic procedures.
